IN8bio (INAB) Biotech Resurgence: Platforms and Pipelines of Today's Innovators summary

Key presentations and scientific insights

• Highlighted gamma delta T cells as a novel therapeutic platform for oncology and autoimmune diseases, with a focus on their unique ability to coordinate immune responses and drive cancer remissions.

• Presented clinical data from glioblastoma programs (INB-200/400), showing improved progression-free and overall survival compared to controls, with statistical significance despite small cohorts.

• Emphasized the absence of major toxicities, including no cytokine release syndrome or neurotoxicity, across clinical trials to date.

• Introduced a proprietary T-cell engager platform targeting CD19, aiming to reset the immune system for autoimmune diseases with reduced toxicity compared to traditional CD3-targeting approaches.

• Demonstrated preclinical data showing effective B-cell depletion and minimal cytokine release, outperforming commercial comparators in safety profile.

Pipeline progress and upcoming milestones

• Ongoing enrollment in leukemia and glioblastoma trials, with clinical updates expected at major conferences (ASH, ASCO) later in the year.

• First animal data for the T-cell engager program anticipated in Q3 or early Q4, which will trigger a second tranche of financing and extend cash runway into 2028.

• Announced an R&D day in May featuring updates across the pipeline and expert commentary from a leading neuro-oncologist.

• Peer-reviewed publication of GBM clinical data is in preparation, with additional operational execution to advance the T-cell engager platform.

• Cash position of $27 million at end of 2025, with milestones tied to further capital infusions and IND submission for the T-cell engager.

Strategic vision and industry context

• Positioned as a platform company leveraging gamma delta T cell expertise to create value for patients, investors, and potential pharma partners.

• Noted recent industry transactions in the T-cell engager space, highlighting significant deal values and validating the commercial potential of the approach.

• Focused on building a differentiated, multi-product pipeline with both near-term and long-term value drivers.

• Emphasized proven execution in delivering clinical milestones and advancing programs despite industry challenges.

• Long-term vision includes potential for partnerships or acquisitions, while maintaining focus on advancing the core platform.